Oral Deforolimus With Trastuzumab for Patients With HER2-positive Trastuzumab-Refractory Metastatic Breast Cancer (8669-009)
Clinical trial NCT00736970 · COMPLETED
Trial details
- NCT number
- NCT00736970
- Sponsor
- Merck Sharp & Dohme LLC
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2008-07-01
- Primary completion
- 2011-01-01
- Enrollment
- 34
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.